IP Library Granted Patent US 12,194,194
Granted Patent B2
US 12,194,194 · App. 17/577,519 · Granted Jan 14, 2025

Soft tissue protein compositions, methods of making, and uses thereof

Inventors: Amit Prakash Govil (Carlsbad, CA); Bryan Choi (Carlsbad, CA); Sahil Jalota (Carlsbad, CA)
Assignee: Advanced Biologics, LLC
A61L27/3687A23J1/02A23J1/04A61L27/3604A61L27/44A61L2430/34A61L2430/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,194,194
App. No.
17/577,519
Granted
Jan 14, 2025
Kind
B2
Abstract

Provided herein are soluble soft tissue protein compositions that can contain one or more soft-tissue bioactive factors, methods of making the soluble soft tissue protein compositions, and methods of using the soluble soft tissue protein compositions.

Claims (21)

1. A dehydrated soluble soft tissue protein composition comprising a bioactive factor, where the dehydrated soluble soft tissue protein composition is made by a method comprising:

harvesting soft tissue from a donor to obtain harvested soft tissue, where the soft tissue contains soft tissue cells;

heating the harvested soft tissue to at least 20° C.;

lysing the soft tissue cells by osmotic shock without a detergent to obtain a soft tissue cell lysate;

isolating the soft tissue lysate from the soft tissue to yield the soluble soft tissue protein composition; and

dehydrating the soluble soft tissue lysate to obtain a dehydrated soluble soft tissue protein composition.

2. The soluble soft tissue protein composition of claim 1 , further comprising the step of fractionating the soft tissue cell lysate via centrifugation to obtain a soluble soft tissue protein fraction after lysing the soft tissue cells.

3. The soluble soft tissue protein composition of claim 1 , wherein heating the harvested soft tissue occurs at about 20° C. to about 40° C.

4. The soluble soft tissue protein composition of claim 1 , further comprising the step of washing the harvested soft tissue.

5. The soluble soft tissue protein composition of claim 4 , wherein the steps of washing the harvested soft tissue, heating the harvested soft tissue, and lysing soft tissue cells occur simultaneously.

6. The soluble soft tissue protein composition of claim 5 , further comprising the step of applying an amount of the dehydrated soluble soft tissue protein composition in stabilization solution to a scaffold.

7. The soluble soft tissue protein composition of claim 1 , further comprising the step of adding a stabilization solution prior to dehydrating.

8. The soluble soft tissue protein composition of claim 1 , further comprising the step of filtering the soluble soft tissue protein fraction.

9. The soluble soft tissue protein composition of claim 1 , further comprising the step of selectively filtering or isolating the soft tissue cells to obtain a desired cell population prior to lysing the soft tissue cells.

10. The soluble soft tissue protein composition of claim 9 , wherein the step of lysing further comprises lysing the desired cell population.

11. The soluble soft tissue protein composition of claim 9 , wherein the desired cell population is adipocytes.

12. The soluble soft tissue protein composition of claim 1 , further comprising the step of applying an amount of the dehydrated soluble soft tissue protein composition to a scaffold.

13. A method of treating a subject in need thereof comprising implanting or administering a soluble soft tissue protein composition of claim 1 .

14. The method of claim 13 , wherein the subject in need thereof has soft tissue damage.

15. The method of claim 13 , wherein the subject in need thereof is in need of a soft tissue graft.

16. The method of claim 13 , wherein the subject in need thereof is in need of a soft tissue augmentation.

Assignments (5)
SECURITY INTEREST Recorded Sep 18, 2025
From: ISTO TECHNOLOGIES II, LLC; ADVANCED BIOLOGICS LLC,; ARTERIOCYTE MEDICAL SYSTEMS, INC.; THERACELL, LLC
To: GOLUB CAPITAL MARKETS LLC
Reel/Frame 072300/0216 →
RELEASE OF SECURITY INTEREST Recorded Sep 16, 2025
From: BARINGS FINANCE LLC, AS COLLATERAL AGENT
To: ARTERIOCYTE MEDICAL SYSTEMS, INC.; ISTO TECHNOLOGIES II, LLC; THERACELL, LLC; ADVANCED BIOLOGICS, LLC; BIOLOGICA TECHNOLOGIES, LLC
Reel/Frame 072274/0408 →
SECURITY INTEREST Recorded Oct 18, 2023
From: ARTERIOCYTE MEDICAL SYSTEMS, INC.; ISTO TECHNOLOGIES II, LLC; THERACELL, LLC; ADVANCED BIOLOGICS, LLC; BIOLOGICA TECHNOLOGIES, LLC
To: BARINGS FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 065271/0059 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2023
From: BIOLOGICA TECHNOLOGIES
To: ADVANCED BIOLOGICS, LLC
Reel/Frame 064551/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2023
From: GOVIL, AMIT PRAKASH; CHOI, BRYAN; JALOTA, SAHIL
To: BIOLOGICA TECHNOLOGIES
Reel/Frame 064519/0443 →
Continuity (3)
Division 15767957
Provisional Application 62240345 · Oct 12, 2015
Related Publication 20220152277A1 · May 19, 2022
References Cited (11)
US 20110151011A1 · Flynn · 2011 [cited by applicant]
US 20120264190A1 · Christman et al. · 2012 [cited by applicant]
US 20130202563A1 · Badylak et al. · 2013 [cited by applicant]
US 20130273658A1 · Damm et al. · 2013 [cited by applicant]
Depalma, “Focus on Cell Disruption,” Lab Manager, Product Focus (Jun. 2015). [cited by applicant]
Chen, et al., “Advancing biomatierals of human origin for tissue engineering,” Progress in Polymer Science, vol. 53 (2015) pp. 86-168. [cited by applicant]
Kleinig, “Cell Disruption Mechanisms,” University of Adelaide, 1997, pp. 1-223. [cited by applicant]
International Search Report for PCT/US2016/056575 of Jan. 12, 2017. [cited by applicant]
Choi, et al, “Decellularized Extracellular Matrix Derived from Porcine Adipose Tissue as a Xenogeneic Biomaterial for Tissue Engineering,” Tissue Engineering C 18(11), 2012, pp. 866-876. [cited by applicant]
Choi, et al., “Human extracellular matrix (ECM) powders for injectable cell delivery and adipose tissue engineering,” J. Controlled Release 129 (2009) pp. 2-7. [cited by applicant]
Choi, et al., “Adipose Tissue: A valuable Resource of Biomaterials for Soft Tissue Engineering,” Macromolecular Research 22(9), (2014) pp. 932-947. [cited by applicant]